Interleukin-1 beta induced-desArg9bradykinin-mediated thermal hyperalgesia in the rat.
The induction of desArg9Bk-mediated thermal hyperalgesia has been studied in the rat. Intraplantar injections of interleukin-1 beta, (IL-1 beta, 1-100 Units, U) produced a 30-40% decrease in withdrawal latency to noxious heat which lasted for up to 24 hr in the treated paw. IL-1 beta-induced thermal hyperalgesia was also present in the contralateral paw for up to 1 hr following IL-1 beta injection. Intraplantar tumour necrosis factor-alpha (TNF alpha, 500 U) also reduced the withdrawal latency in the u.v.-treated paw with recovery by 18 hr but with no contralateral hyperalgesia. Forty-eight hr after IL-1 beta but not after TNF alpha administration, desArg9Bk (10 nmol/kg i.v.) reduced the withdrawal latency in both the ipsi- and contra-lateral paws by 30-49%. In naive animals, desArg9Bk was without effect. These data suggest that, in the rat, IL-1 beta but not TNF alpha can lead to the induction of bradykinin B1 receptors mediating thermal hyperalgesia.
Perkins
M N
MN
Sandoz Institute for Medical Research, London, U.K.
Kelly
D
D
D000818:Animals; D001920:Bradykinin / Q000031:analogs & derivatives* / Q000494:pharmacology; D065168:Bradykinin Receptor Antagonists; D005260:Female; D006358:Hot Temperature; D006930:Hyperalgesia / Q000503:physiopathology*; D007375:Interleukin-1 / Q000494:pharmacology*; D010147:Pain Measurement / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D018002:Receptors, Bradykinin / Q000819:agonists; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology
D065168:Bradykinin Receptor Antagonists; D007375:Interleukin-1; D018002:Receptors, Bradykinin; D014409:Tumor Necrosis Factor-alpha; C024626:bradykinin, des-Arg(9)-; D001920:Bradykinin